Teva Pharmaceutical Industries Ltd. has entered an agreement to buy Bentley Pharmaceuticals. The move will follow the spin-off of Bentley’s drug delivery business, which was announced in October 2007. Teva will spend approximately $360 million to acquire Bentley, which will consist solely of the generic pharmaceutical operations. Bentley manufactures and markets a portfolio of 130 pharmaceutical products in various dosages and strengths, as both branded generic and generic products, to ...